Teva Pharmaceutical Industries Limited (TLV:TEVA)
| Market Cap | 105.71B |
| Revenue (ttm) | 55.55B |
| Net Income (ttm) | 2.36B |
| Shares Out | n/a |
| EPS (ttm) | 2.04 |
| PE Ratio | 44.78 |
| Forward PE | 10.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,493,772 |
| Average Volume | 1,372,652 |
| Open | 9,005.00 |
| Previous Close | 8,891.00 |
| Day's Range | 8,967.00 - 9,166.00 |
| 52-Week Range | 4,865.00 - 9,166.00 |
| Beta | 0.70 |
| RSI | 78.37 |
| Earnings Date | Jan 28, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial numbers in USD Financial StatementsNews
Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions. Pfizer is stabilizing af...
Teva Pharmaceutical (TEVA) Receives Sector Outperform Rating from Scotiabank | TEVA Stock News
Teva Pharmaceutical (TEVA) Receives Sector Outperform Rating from Scotiabank | TEVA Stock News
Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference Transcript
Israel Has Been Mired In Controversy During Its War With Hamas. Big Tech Investment Tells A Different Story.
Israel's stock market has outpaced U.S. markets since Oct. 7, 2023, with U.S.-traded leaders like Teva, Elbit Systems and Tower Semiconductor showing big gains.
TEVA Forecasts Significant Rise in Cash Flow by 2030
TEVA Forecasts Significant Rise in Cash Flow by 2030
Noteworthy ETF Inflows: IEFA, SPOT, SE, TEVA
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI EAFE ETF (Symbol: IEFA) where we have detected an ap...
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks
Druckenmiller invests his personal and family's wealth through his fund, the Duquesne Family Office. Druckenmiller is high on biotech stocks, with his top three holdings at the end of the third quarte...
Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd?
Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) short interest as a percent of float has risen 6.52% since its last report. According to exchange reported data, there are now 50.39 million shares s...
Teva: European Commission Grants Marketing Authorizations For Biosimilars PONLIMSI, DEGEVMA
(RTTNews) - Teva Pharmaceuticals International, a subsidiary of Teva Pharmaceutical Industries (TEVA), announced that the European Commission has granted marketing authorizations for its two denosumab...
Teva (TEVA) Gains European Approval for Denosumab Biosimilars
Teva (TEVA) Gains European Approval for Denosumab Biosimilars
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
TEL AVIV, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced that the European Comm...
This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now.
Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing. He’s now piling into Natera (NASDAQ:NTRA), Insmed (NASD...
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December
TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of execu...
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December
TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of execu...
Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report
A federal jury has convicted Ruthia He, the founder of the telehealth startup Done Global, for orchestrating a scheme that transformed the company into an unrestricted source for Adderall prescription...
Teva (TEVA) Launches Innovative Platform to Drive Technological Advancement
Teva (TEVA) Launches Innovative Platform to Drive Technological Advancement
Teva seeks startups to help solve global pharmaceutical challenges
Teva Pharmaceutical Industries said on Wednesday it was calling on startups to join its new platform to develop technologies to deal with a host of challenges facing Teva and the global pharmaceutical...
Insider Sell: Christine Fox Sells 30,000 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Insider Sell: Christine Fox Sells 30,000 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare Conference 2025 Transcript
Gleview Capital Adjusts Portfolio, Increases Stake in Teva Pharmaceutical (TEVA)
Gleview Capital Adjusts Portfolio, Increases Stake in Teva Pharmaceutical (TEVA)
Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business
See how Teva Pharmaceutical Industries Limited's growth strategy and focus on specialty medicines are driving a turnaround. Click for more on TEVA and its earnings.
Insider Selling: Amir Weiss Unloads $300K Of Teva Pharmaceutical Indus Stock
A substantial insider sell was reported on November 10, by Amir Weiss , Chief Accounting Officer at Teva Pharmaceutical Indus (NYSE: TEVA), based on the recent SEC filing. What Happened: A Form 4 fil...
Billionaire Stanley Druckenmiller Sold His Fund's Entire Stakes in Nvidia and Palantir for a Scorching-Hot Drug Stock That's Up 218% Since Mid-2023
Quarterly-filed Form 13Fs can clue investors into which stocks and trends are piquing the interest of Wall Street's brightest money managers. Billionaire Stanley Druckenmiller dumped his fund's holdin...
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
Teva Pharmaceutical Indus (NYSE: TEVA) has outperformed the market over the past 5 years by 6.92% on an annualized basis producing an average annual return of 20.65%. Currently, Teva Pharmaceutical I...